Comparative Pharmacology
Head-to-head clinical analysis: AVANDIA versus SYNJARDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDIA versus SYNJARDY.
AVANDIA vs SYNJARDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver.
SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin inhibits DPP-4, increasing incretin hormone levels (GLP-1, GIP), which stimulate insulin release and decrease glucagon secretion.
Initial dose 4 mg orally once daily; may increase to 8 mg once daily or 4 mg twice daily if inadequate glycemic control after 8-12 weeks. Maximum dose 8 mg/day.
Initial: 5 mg empagliflozin/1000 mg metformin hydrochloride extended-release orally twice daily with meals. Titrate based on glycemic control, up to maximum of 25 mg/2000 mg per day (given as 12.5 mg/1000 mg twice daily).
None Documented
None Documented
3-4 hours (terminal elimination half-life). No clinically significant accumulation with once-daily dosing.
Empagliflozin: terminal half-life ~12.4 hours (supports once-daily dosing). Metformin: terminal half-life ~6.2 hours in plasma, but prolonged to ~17.6 hours in whole blood due to RBC binding; clinical effect duration aligns with daily dosing.
Primarily hepatic metabolism via CYP2C8, with minimal renal excretion of unchanged drug (<1%). Approximately 64% of the dose is excreted in urine as metabolites and 23% in feces as metabolites.
Renal: ~95% of empagliflozin as unchanged drug; ~20% of metformin as unchanged drug via glomerular filtration and tubular secretion. Fecal: <1% for empagliflozin; ~30% of metformin as unchanged drug. Biliary: negligible.
Category C
Category C
Antidiabetic
Antidiabetic